The latest biotech news

News and Trends 1 Nov 2022

Tetris Pharma launches hypoglycemia injector pen in Germany

Tetris Pharma Ltd, a subsidiary of biopharma company Arecor Therapeutics plc, has launched Ogluo (glucagon prefilled autoinjector pen) in Germany as a treatment for severe hypoglycemia in children and adults living with diabetes. Ogluo is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycemia. […]

November 1, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Nov 2022

Human Immunology Biosciences launches with $120M

Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced its launch with $120 million in financing. HI-Bio was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family offices. Few targeted therapies exist for the autoimmune, allergic […]

November 1, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

First patient enrolled and dosed on expansion phase of cancer treatment trial

The first patient in an expansion phase of a trial looking at cancer drug Modi-1 has been enrolled and dosed. Scancell Holdings plc, the developer of immunotherapies for the treatment of cancer and infectious disease made the announcement today (October 31). The expansion phase is part of the monotherapy arms of the phase 1 clinical […]

October 31, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

Researchers develop efficient nanovaccine delivery system boosting cellular immunity

A research group has successfully developed a new nanovaccine delivery system, to strongly activate cellular immunity, using one-tenth of the amount of antigen that was previously required. Led by Eiji Yuba, an associate professor at the Graduate School of Engineering at Osaka Metropolitan University in Japan, the group has been developing been developing the […]

October 31, 2022 - 3 minutesmins - By Liza Laws

AMR antimicrobial resistance antibiotics

News and Trends 31 Oct 2022

Efflux pump inhibitor research may lead way to beating AMR

Researchers from SANKEN (The Institute of Scientific and Industrial Research), at Osaka University in Japan have provided new insights into the relationship between the position of “bulky” amino acids on bacterial proteins and the ability of bacteria to resist antibiotics. The medical profession is losing a race. Bacterial antibiotic resistance doesn’t only threaten the ability […]

October 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Replay Bio launches HSV gene therapy company to target retinal eye disease

Replay Bio has announced the launch of Eudora, an HSV (herpes simplex virus) gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Eudora’s co-founders Joe Glorioso, Mark Blumenkranz, David Schaffer, and Vinit Mahajan, are entrepreneurs who have worked in […]

October 31, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Scientists say RNA production inhibitors important in cancer research

A study by researchers at the Biomedical Institute of Seville (IBIS) and the University of Seville, in collaboration with the Danish Cancer Society, shows that inhibiting RNA synthesis after radiation therapy facilitates the death of tumor cells. The study was published in the journal Nature Communications. RNA has been shown to be essential for repairing […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Startup BioRaptor raises $3M to drive AI insights for scientists

BioRaptor has raised $3M in funding, which it says will allow it to put the power of AI-generated insights into the hands of every scientist. The round was led by lool Ventures and CPT Capital and was joined by FoodHack and other strategic angel investors. BioRaptor is building an operating system for biology research and […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

U.K. biopharma company PhoreMost Ltd. has entered into a multi-target collaboration with Arvinas, a company active in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Reprogramming immune cells can fight melanoma

A new way of reprogramming immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard-to-treat skin cancer, melanoma. The University of Bristol, in the U.K. led the discovery, which has been published in Advanced Science. It demonstrates a new way to clear early stage pre-cancerous and even […]

October 31, 2022 - 3 minutesmins - By Jim Cornall

elypta renal cell carcinoma kidney cancer

News and Trends 28 Oct 2022

Rila Therapeutics exits stealth mode to address renal fibrosis

Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, has emerged from stealth mode. Rila Therapeutics has identified a promising, first-in-class allosteric small molecule targeting HIPK2 to inhibit kidney fibrosis. The breakthrough discovery aiming to advance the treatment of renal disease was developed in collaboration with Mount […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

AKT inhibitor ipatasertib shows signs of effectiveness in patient trial

News and Trends 28 Oct 2022

AKT inhibitor shows signs of effectiveness in patient trial

In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In the majority […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Tetris Pharma launches hypoglycemia injector pen in Germany

Human Immunology Biosciences launches with $120M

First patient enrolled and dosed on expansion phase of cancer treatment trial

Researchers develop efficient nanovaccine delivery system boosting cellular immunity

Efflux pump inhibitor research may lead way to beating AMR

Replay Bio launches HSV gene therapy company to target retinal eye disease

Scientists say RNA production inhibitors important in cancer research

Startup BioRaptor raises $3M to drive AI insights for scientists

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

Reprogramming immune cells can fight melanoma

Rila Therapeutics exits stealth mode to address renal fibrosis

AKT inhibitor shows signs of effectiveness in patient trial

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!